467 related articles for article (PubMed ID: 31463793)
41. Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER
Formisano L; Stauffer KM; Young CD; Bhola NE; Guerrero-Zotano AL; Jansen VM; Estrada MM; Hutchinson KE; Giltnane JM; Schwarz LJ; Lu Y; Balko JM; Deas O; Cairo S; Judde JG; Mayer IA; Sanders M; Dugger TC; Bianco R; Stricker T; Arteaga CL
Clin Cancer Res; 2017 Oct; 23(20):6138-6150. PubMed ID: 28751448
[No Abstract] [Full Text] [Related]
42. HOXB7 Is an ERα Cofactor in the Activation of HER2 and Multiple ER Target Genes Leading to Endocrine Resistance.
Jin K; Park S; Teo WW; Korangath P; Cho SS; Yoshida T; Győrffy B; Goswami CP; Nakshatri H; Cruz LA; Zhou W; Ji H; Su Y; Ekram M; Wu Z; Zhu T; Polyak K; Sukumar S
Cancer Discov; 2015 Sep; 5(9):944-59. PubMed ID: 26180042
[TBL] [Abstract][Full Text] [Related]
43. Identification of estrogen receptor α ligands with virtual screening techniques.
Niinivehmas SP; Manivannan E; Rauhamäki S; Huuskonen J; Pentikäinen OT
J Mol Graph Model; 2016 Mar; 64():30-39. PubMed ID: 26774287
[TBL] [Abstract][Full Text] [Related]
44. Oral Selective Estrogen Receptor Downregulators (SERDs), a Breakthrough Endocrine Therapy for Breast Cancer.
McDonnell DP; Wardell SE; Norris JD
J Med Chem; 2015 Jun; 58(12):4883-7. PubMed ID: 26039356
[TBL] [Abstract][Full Text] [Related]
45. Novel Selective Estrogen Receptor Ligand Conjugates Incorporating Endoxifen-Combretastatin and Cyclofenil-Combretastatin Hybrid Scaffolds: Synthesis and Biochemical Evaluation.
Kelly PM; Keely NO; Bright SA; Yassin B; Ana G; Fayne D; Zisterer DM; Meegan MJ
Molecules; 2017 Aug; 22(9):. PubMed ID: 28858267
[TBL] [Abstract][Full Text] [Related]
46. A short-incubation reporter-gene assay for high-throughput screening of estrogen receptor-alpha antagonists.
Shi X; Zheng W; Schneeweis JE; Fischer PA; Strulovici B; Peekhaus NT
Assay Drug Dev Technol; 2005 Aug; 3(4):393-400. PubMed ID: 16180994
[TBL] [Abstract][Full Text] [Related]
47. Role of estrogen receptor alpha transcriptional coregulators in tamoxifen resistance in breast cancer.
Girault I; Bièche I; Lidereau R
Maturitas; 2006 Jul; 54(4):342-51. PubMed ID: 16822624
[TBL] [Abstract][Full Text] [Related]
48. Elucidation of Agonist and Antagonist Dynamic Binding Patterns in ER-α by Integration of Molecular Docking, Molecular Dynamics Simulations and Quantum Mechanical Calculations.
Sakkiah S; Selvaraj C; Guo W; Liu J; Ge W; Patterson TA; Hong H
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502280
[TBL] [Abstract][Full Text] [Related]
49. Systems Structural Biology Analysis of Ligand Effects on ERα Predicts Cellular Response to Environmental Estrogens and Anti-hormone Therapies.
Nwachukwu JC; Srinivasan S; Bruno NE; Nowak J; Wright NJ; Minutolo F; Rangarajan ES; Izard T; Yao XQ; Grant BJ; Kojetin DJ; Elemento O; Katzenellenbogen JA; Nettles KW
Cell Chem Biol; 2017 Jan; 24(1):35-45. PubMed ID: 28042045
[TBL] [Abstract][Full Text] [Related]
50. Balanced dual acting compounds targeting aromatase and estrogen receptor α as an emerging therapeutic opportunity to counteract estrogen responsive breast cancer.
Caciolla J; Martini S; Spinello A; Pavlin M; Turrini E; Simonelli F; Belluti F; Rampa A; Bisi A; Fimognari C; Zaffaroni N; Gobbi S; Magistrato A
Eur J Med Chem; 2021 Nov; 224():113733. PubMed ID: 34364162
[TBL] [Abstract][Full Text] [Related]
51. Dynamacophore model for breast cancer estrogen receptor alpha as an effective lead generation screening technique.
Shanmugarajan D; Biju A; Sibi D; Sibi R; Shaji M; David C
J Biomol Struct Dyn; 2023; 41(22):13029-13040. PubMed ID: 37154819
[TBL] [Abstract][Full Text] [Related]
52. Therapeutic targeting in the estrogen receptor hormonal pathway.
Katzenellenbogen BS; Frasor J
Semin Oncol; 2004 Feb; 31(1 Suppl 3):28-38. PubMed ID: 15052541
[TBL] [Abstract][Full Text] [Related]
53. Novel tumor necrosis factor-α (TNF-α) inhibitors from small molecule library screening for their therapeutic activity profiles against rheumatoid arthritis using target-driven approaches and binary QSAR models.
Zaka M; Abbasi BH; Durdagi S
J Biomol Struct Dyn; 2019 Jun; 37(9):2464-2476. PubMed ID: 30047845
[TBL] [Abstract][Full Text] [Related]
54. Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology.
Katzenellenbogen BS; Choi I; Delage-Mourroux R; Ediger TR; Martini PG; Montano M; Sun J; Weis K; Katzenellenbogen JA
J Steroid Biochem Mol Biol; 2000 Nov; 74(5):279-85. PubMed ID: 11162936
[TBL] [Abstract][Full Text] [Related]
55. Reversal of the estrogen receptor negative phenotype in breast cancer and restoration of antiestrogen response.
Bayliss J; Hilger A; Vishnu P; Diehl K; El-Ashry D
Clin Cancer Res; 2007 Dec; 13(23):7029-36. PubMed ID: 18056179
[TBL] [Abstract][Full Text] [Related]
56. Discovery of potent ligands for estrogen receptor beta by structure-based virtual screening.
Shen J; Tan C; Zhang Y; Li X; Li W; Huang J; Shen X; Tang Y
J Med Chem; 2010 Jul; 53(14):5361-5. PubMed ID: 20553023
[TBL] [Abstract][Full Text] [Related]
57. Antagonists for Constitutively Active Mutant Estrogen Receptors: Insights into the Roles of Antiestrogen-Core and Side-Chain.
Sharma A; Toy W; Guillen VS; Sharma N; Min J; Carlson KE; Mayne CG; Lin S; Sabio M; Greene G; Katzenellenbogen BS; Chandarlapaty S; Katzenellenbogen JA
ACS Chem Biol; 2018 Dec; 13(12):3374-3384. PubMed ID: 30404440
[TBL] [Abstract][Full Text] [Related]
58. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
Søiland H; Skaland I; Varhaug JE; Kørner H; Janssen EA; Gudlaugsson E; Baak JP; Søreide JA
Acta Oncol; 2009; 48(4):514-21. PubMed ID: 19107621
[TBL] [Abstract][Full Text] [Related]
59. Novel SERMs based on 3-aryl-4-aryloxy-2H-chromen-2-one skeleton - A possible way to dual ERα/VEGFR-2 ligands for treatment of breast cancer.
Luo G; Li X; Zhang G; Wu C; Tang Z; Liu L; You Q; Xiang H
Eur J Med Chem; 2017 Nov; 140():252-273. PubMed ID: 28942113
[TBL] [Abstract][Full Text] [Related]
60. Estrogen receptor beta activates the human retinoic acid receptor alpha-1 promoter in response to tamoxifen and other estrogen receptor antagonists, but not in response to estrogen.
Zou A; Marschke KB; Arnold KE; Berger EM; Fitzgerald P; Mais DE; Allegretto EA
Mol Endocrinol; 1999 Mar; 13(3):418-30. PubMed ID: 10076999
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]